Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 2972-2982

  Litvinov, Ivan V ^a,b   De Marzo, Angelo M ^a,b   Isaacs, John T ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RESPONSE ELEMENT; UNCLASSIFIED DRUG;

CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HETEROGENEITY; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROSTATE EPITHELIUM; REVIEW; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; DRUG DESIGN; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 0038637317     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-022038     Document Type: Review

References (108)

1. Isaacs JT 1983 Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate 4:351-366
2. Carter B, Pianpadosi S, Isaacs JT 1990 Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143:742-746
3. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT 1995 Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480
4. Isaacs JT 1994 Role of androgens in prostatic cancer. Vitam Horm 49:433-502
5. Prostate Cancer Trialists' Collaborative Group 1995 Maximum androgen blockade in advances prostate cancer: an overview of 22 randomized trials with 3238 deaths in 5710 patients. Lancet 346:265-269
6. Gottlieb B, Vasillou DM, Lumbroso R, Beitel LK, Pinsky L, Trifiro MA 1999 Analysis of exon 1 mutations in the androgen receptor gene. Hum Mutat 14:527-539
7. Bonkhoff H 1998 Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 8:18-22
8. Isaacs JT 1987 Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: Rogers CH, Coffey DS, Cunha G, Grayhack J, Hinman F, Horton R, eds. Benign prostatic hyperplasia. Report No. INH 87-2881, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, p 85-94
9. Isaacs JT, Coffey DS 1989 Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33-50
10. Bonkhoff H, Stein U, Remberger K 1994 Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25:42-46
11. Bonkhoff H, Remberger K 1996 Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth - a stem cell model. Prostate 28:98-106
12. Robinson EJ, Neal DE, Collins AT 1998 Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostate epithelium. Prostate 37:149-160
13. Van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J 2000 Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 80:1251-1258
14. Hudson DL, O'Hare M, Watt FM, Master JR 2000 Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 80:1243-1250
15. 1-integrin expression. J Cell Sci 114:3865-3872
16. Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE 2002 Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 99:401-406
17. Signoretti, S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M 2000 p63 Is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769-1775
18. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Van Woude GF, Knudsen BS 2001 Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159:579-590
19. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML 1992 Expression of the protooncogene Bcl-2 in the prostate and association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
20. Bonkhoff H, Stein U, Remberger K 1994 The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118
21. Bonkhoff H, Fixemer T, Remberger K 1998 Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 34:251-258
22. Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E, Berger P 2002 Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 53:101-108
23. De Marzo AM, Meeker AK, Epstein JI, Coffey DS 1998 Prostate stem cell compartments: expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153:911-919
24. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG 1997 Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49:857-862
25. Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, Linehan WM, Ferretti JA 2001 Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol 165:1329-1334
26. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH 1997 Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634
27. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE 2002 Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 16:2323-2337
28. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT 1997 Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507-2511
29. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR 1996 Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051
30. Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS, Russell PJ, Heston WD, Molloy PL 2001 A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73:243-254
31. Zelivianski S, Igawa T, Lira S, Taylor R, Lin M 2002 Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene 21:3696-3705
32. Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CYF 2000 An androgen response element media tes LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 168:89-99
33. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y 1987 The endocrinology and developmental biology of the prostate. Endocr Rev 8:338-362
34. Hayward SW, Del Buono R, Deshpande N, Hall PA 1992 A functional model of adult human prostate epithelium: the role of androgens and stroma in architectural organization and the maintenance of differentiated secretory function. J Cell Sci 102:361-372
35. Kurita T, Wany YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR 2001 Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8:192-200
36. Bonkhoff H, Stein U, Aumuller G, Remberger K 1996 Differential expression of 5 α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29:261-267
37. Gerdes MJ, Larsen M, McBride L, Dang TD, Lu B, Rowley DR 1998 Localization of transforming growth factor-β1 and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem 46:379-388
38. Peehl DM, Sellers RG 1997 Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 232:208-215
39. Yang G, Timme TL, Park SH, Thompson TC 1997 Transforming growth factor β 1 transduced mouse prostate reconstitutions. I. Induction of neuronal phenotypes. Prostate 33:151-156
40. Kyprianou N, Isaacs JT 1989 Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522
41. Wikstrom P, Westin P, Stattin P, Damber JE, Bergh A 1999 Early castration-induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 38:268-277
42. Lu W, Luo Y, Kan M, McKeehan WL 1999 Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274:12827-12834
43. Planz B, Aretz HT, Wang Q, Tabatabaei S, Kirley SD, Lin CW, McDougal WS 1999 Immunolocalization of the keratinocyte growth factor in benign and neoplastic human prostate and its relation to androgen receptor. Prostate 41:233-242
44. 1 on proliferation and death of rat prostatic cells. Endocrinology 127:2963-2968
45. Denmeade SR, Lin XS, Isaacs JT 1996 Role of programmed (apoptotic) cell death during the progression and therapy of prostate cancer. Prostate 28:251-265
46. Kyprianou N, Isaacs JT 1988 Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562
47. Kyprianou N, English HF, Isaacs JT 1988 Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13:103-117
48. Lissbrant IF, Lissbrant E, Damber JE, Bergh A 2001 Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35:437-452
49. English HF, Santen RJ, Isaacs JT 1987 Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229-242
50. Kasai S, Sugimura K, Matsumoto K, Nishi N, Kishimoto T, Nakamura T 1996 Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem Biophys Res Commun 228:646-652
51. Liu AY, Peehl DM 2001 Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res 305:389-397
52. Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Powell IJ, Sarkar FH 1996 Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia, and primary prostate carcinoma. J Cell Physiol 169:269-280
53. Geck P, Szelei J, Jimenez J, Lin TM, Sonnenschein C, Soto AM 1997 Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. J Steroid Biochem Mol Biol 63:211-218
54. Ling MT, Chan KW, Choo CK 2001 Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170:287-296
55. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL 2002 Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 13:1-11
56. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ 1996 Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7:1571-1578
57. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J 2000 Involvement of p27Kip1 in G1 arrest by high dose 5α-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19:670-679
58. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M 2001 Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15:765-782
59. Lu L, Schulz H, Wolf DA 2002 The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 3:22
60. McNeal JE, Bostwick DG 1986 Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17:64-71
61. De Marzo AM, Nelson WG, Meeker AK, Coffey DS 1998 Stem cell features of benign and malignant prostate epithelial cells. J Urol 160:2381-2392
62. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J 2002 Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51:98-107
63. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA 1992 Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182-6187
64. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, DeMarzo AM 2002 Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 62:6406-6409
65. De Marzo AM, Marchi VL, Epstein JI, Nelson WG 1999 Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992
66. De Marzo AM, Putzi MJ, Nelson WG 2001 New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57(Suppl 1):103-114
67. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM, Nelson WG 2001 GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 159:1815-1826
68. Gao J, Isaacs JT 1998 Development of an androgen receptor null model for identifying the site of initiation for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 58:3299-3306
69. Gao J, Arnold JT, Isaacs JT 2001 Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61:5038-5044
70. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW 2002 Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEn and with reduced recurrence-free survival. Clin Cancer Res 8:3419-3426
71. Kyprianou N, English H, Isaacs JT 1990 Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3752
72. Isaacs JT 1999 The biology of hormone refractory prostate cancer: why does it develop? In: Urologic Clinics of North America. Vol 26. Philadelphia: WB Saunders Company; 263-273
73. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A 1996 Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129-135
74. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515
75. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TLJ, Vessella RL, Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555
76. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555
77. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR 2002 Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198:237-244
78. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD 2001 Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281
79. Hyytinen ER, Haapla K, Thompson J, Lappalainen I, Roiha M, Rantal I, Helin HJ, Janne OA, Vihinen M, Palvimo JJ, Koivisto PA 2002 Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 82:1591-1598
80. Chen S, Song CS, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B, Roy AK 1998 Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 12:1558-1566
81. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H 2002 Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9:117-125
82. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013
83. Chadli A, Bouhouche I, Sullivan W, Stensgard B, McMahon N, Catelli MG, Tort DO 2000 Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc Natl Acad Sci USA 97:12524-12529
84. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990
85. Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C 2001 Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents 15:123-129
86. He B, Bowen NT, Minges JT, Wilson EM 2001 Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293-42301
87. Shang Y, Myers M, Brown M 2002 Formation of the androgen receptor transcription complex. Mol Cell 9:601-610
88. Kang Z, Pirskanen A, Janne OA, Palvimo JJ 2002 Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371
89. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley BW 1998 Partial hormone resistance in mice with disruption of the steroid receptor coativator-1 (SRC-1) gene. Science 279:1922-1925
90. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper CG, Jenser G, Trapman J, Brinkman AO, Mulder E 1992 The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to androgens. J Steroid Biochem Mol Biol 41:665-669
91. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D 2000 Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706
92. Huang Z-Q, Li J, Wong J 2002 AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16:924-937
93. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
94. Craft N, Shostak Y, Carey M, Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285
95. Nazareth LV, Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907
96. Sadar MD 1999 Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783
97. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z 1998 Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645
98. Ueda T, Mawji NR, Bruchovsky N, Sadar MD 2002 Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094
99. Chen T, Wang LH, Farrar WL 2000 Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60:2132-2135
100. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug B, Nelson JB, Gao AC 2002 Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52:123-129
101. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N 2002 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
102. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT 2003 Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2 and PSMA in human prostate cancer models. Prostate 54:249-257
103. Lu S, Jenster G, Epner DE 2000 Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14:753-760
104. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY 2002 Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 21:5069-5080
105. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91:1869-1876
106. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Harkonen PL 2001 Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 81:815-826
107. Song Z, Wu X, Powell WC, Cardiff RD, Cohen MD, Tin RT, Matusik RJ, Miller GJ, Roy-Burman P 2002 Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intra-epithelial neoplasia. Cancer Res 62:5096-5105
108. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM 1999 Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate 39:8-15